From: Spectrum of malignant and premalignant skin lesions in 505 adult subjects at risk of skin cancers
Univariate OR | P-value | 95% CI | Multivariate OR | P-value | 95% CI | |
---|---|---|---|---|---|---|
Age years | 1.169 | < 0.001 | 1.099–1.242 | 1.388 | < 0.001 | 1.163–1.656 |
Sex | ||||||
Male | 1 (ref) | 0.441 | 0.337–1.606 | 1 (ref) | ||
Female | 0.736 | 5.653 | 0.144 | 0.554–57.715 | ||
Immunosuppression | ||||||
No | 1 (ref) | 0.265 | 0.544–9.177 | 1 (ref) | 0.303 | 0.161–354.972 |
Yes | 2.234 | 7.570 | ||||
Occupation type | ||||||
mainly indoor | 1 (ref) | 0.015 | 1.231–6.934 | 1 (ref) | 0.350 | 0.353–18.937 |
mainly outdoor/mix | 2.922 | 2.586 | ||||
Lifetime sunburns | ||||||
rarely | 1 (ref) | 1 (ref) | ||||
occasionally | 0.207 | 0.005 | 0.069–0.619 | 0.038 | 0.007 | 0.004–0.401 |
often | 0.500 | 0.249 | 0.154–1.624 | 4.068 | 0.311 | 0.269–61.560 |
Number of moles | ||||||
0–20 | 1 (ref) | 1 (ref) | ||||
21–50 | 0.271 | 0.016 | 0.093–0.785 | 0.111 | 0.071 | 0.010–1.204 |
51–100 | 0.290 | 0.037 | 0.091–0.927 | 1.563 | 0.723 | 0.132–18.526 |
over 100 mol | 0.243 | 0.028 | 0.069–0.856 | 2.967 | 0.617 | 0.042–210.301 |
ASA use | ||||||
no | 1 (ref) | 1 (ref) | ||||
occasional | 0.697 | 0.639 | 0.154–3.153 | 0.010 | 0.031 | 0.000–0.666 |
regular | 3.152 | 0.023 | 1.170–8.489 | 4.610 | 0.214 | 0.414–51.354 |
NSAID use | ||||||
no | 1 (ref) | 1 (ref) | ||||
occasional | 0.382 | 0.028 | 0.162–0.900 | 0.572 | 0.591 | 0.075–4.372 |
regular | 0.441 | 0.269 | 0.104–1.881 | 0.062 | 0.135 | 0.002–2.374 |
Platelet-to-lymphocyte-ratio | 1.004 | 0.371 | 0.996–1.012 | 1.028 | 0.023 | 1.004–1.053 |
Family history of MM | ||||||
No | 1 (ref) | 1 (ref) | ||||
One MM case in family | 1.696 | 0.475 | 0.398–7.229 | 50.273 | 0.078 | 0.645–3916.795 |
2 or more MM cases | 0.283 | 0.135 | 0.054–1.481 | 0.062 | 0.098 | 0.002–1.670 |
AMS | ||||||
no | 1 (ref) | 1 (ref) | ||||
yes | 0.343 | 0.066 | 0.110–1.073 | 0.060 | 0.119 | 0.002-2.056 |